T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

Hui, Enfu, Cheung, Jeanne, Zhu, Jing, Su, Xiaolei, Taylor, Marcus J., Wallweber, Heidi A., Sasmal, Dibyendu K., Huang, Jun +3 more·2017·Science
DOI 10.1126/science.aaf1292

Cited by (1,002)

Items 101–200 of 1,002

  1. PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals
    Rémi Fromentin, Sandrina DaFonseca, Cecilia Theresa Costiniuk, Mohamed El Far, Francesco A. Procopio, Frederick M. Hecht, Rebecca Hoh, Steven G. Deeks, Daria J. Hazuda, Sharon R. Lewin et al. · 2019 · Nature Communications
  2. T cell factor 1: A master regulator of the T cell response in disease
    Escobar, Giulia, Mangani, Davide, Anderson, Ana C. · 2020 · Science Immunology
  3. A nanounit strategy reverses immune suppression of exosomal PD-L1 and is associated with enhanced ferroptosis
    Guohao Wang, Lisi Xie, Bei Li, Wei Sang, Jie Yan, Jie Li, Hao Tian, Wenxi Li, Zhan Zhang, Ye Tian et al. · 2021 · Nature Communications
  4. Combinations of Bevacizumab With Cancer Immunotherapy
    Daniel S. Chen, Herbert I. Hurwitz · 2018 · The Cancer Journal
  5. The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors
    Kyung Hwan Kim, Jinhyun Cho, Bo Mi Ku, Jiae Koh, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Jaekyung Cheon, Young Joo Min, Su‐Hyung Park et al. · 2019 · Clinical Cancer Research
  6. Integrative Approaches to Cancer Immunotherapy
    Gregory Lee Szeto, Stacey D. Finley · 2019 · Trends in cancer
  7. Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action
    Zena N. Willsmore, Ben G T Coumbe, Silvia Crescioli, Sara Reci, Ayushi Gupta, R. J. C. Harris, Alicia M. Chenoweth, Jitesh Chauhan, Heather J. Bax, Alexandra J. McCraw et al. · 2021 · European Journal of Immunology
  8. T follicular helper cells in germinal center B cell selection and lymphomagenesis
    Michelle A. Mintz, Jason G. Cyster · 2020 · Immunological Reviews
  9. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
    Hao Wang, Gurbakhash Kaur, Alexander I. Sankin, Fuxiang Chen, Fangxia Guan, Xingxing Zang · 2019 · Journal of Hematology & Oncology
  10. The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response
    Merav Cohen, Amir Giladi, Oren Barboy, Pauline Hamon, Baoguo Li, Mor Zada, Anna Gurevich‐Shapiro, Cristian G. Beccaría, Eyal David, Barbara B. Maier et al. · 2022 · Nature Cancer
  11. Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
    Miren Zuazo, Hugo Arasanz, G. Fernández-Hinojal, María Jesús García-Granda, María Gato, Ana Bocanegra, Berta Hernández, Maite Martínez, Lucía Teijeira, Idoia Morilla et al. · 2019 · EMBO Molecular Medicine
  12. Multiple Signaling Roles of CD3ε and Its Application in CAR-T Cell Therapy
    Wei Wu, Qiuping Zhou, Takeya Masubuchi, Xiaoshan Shi, Hua Li, Xinyi Xu, Min Huang, Meng Li, Xing He, Hengyu Zhu et al. · 2020 · Cell
  13. Chronic Implant-Related Bone Infections—Can Immune Modulation be a Therapeutic Strategy?
    Elisabeth Seebach, Katharina F. Kubatzky · 2019 · Frontiers in Immunology
  14. Activation or exhaustion of CD8+ T cells in patients with COVID-19
    Min‐Seok Rha, Eui‐Cheol Shin · 2021 · Cellular and Molecular Immunology
  15. Emerging concepts in PD-1 checkpoint biology
    Kristen E. Pauken, James Anthony Torchia, Apoorvi Chaudhri, Arlene H. Sharpe, Gordon James Freeman · 2021 · Seminars in Immunology
  16. Size/Charge Changeable Acidity‐Responsive Micelleplex for Photodynamic‐Improved PD‐L1 Immunotherapy with Enhanced Tumor Penetration
    Liangliang Dai, Ke Li, Menghuan Li, Xiaojing Zhao, Zhong Yuan Luo, Lu Lu, Yanfeng Luo, Kaiyong Cai · 2018 · Advanced Functional Materials
  17. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models
    Robert D. Leone, Im-Meng Sun, Min Hee Oh, Im‐Hong Sun, Jiayu Wen, Judson M. Englert, Jonathan D. Powell · 2018 · Cancer Immunology Immunotherapy
  18. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation
    Jaikumar Duraiswamy, Riccardo Turrini, Aspram Minasyan, David Barras, Isaac Crespo, Alizée J Grimm, Julia Casado, Raphaël Genolet, Fabrizio Benedetti, Alexandre M. Wicky et al. · 2021 · Cancer Cell
  19. Modulation of regulatory T cell function and stability by co-inhibitory receptors
    Liliana E. Lucca, Margarita Dominguez‐Villar · 2020 · Nature reviews. Immunology
  20. Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells
    Yunlong Zhao, Devin L. Harrison, Yuran Song, Jie Ji, Jun Huang, Enfu Hui · 2018 · Cell Reports
  21. Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell–Mediated Inflammation and Immunosuppression
    Wenwen Xu, Juan Dong, Yongwei Zheng, Juan Zhou, Ying Yuan, Hieu Minh Ta, Halli E. Miller, Michael Olson, Kamalakannan Rajasekaran, Marc S. Ernstoff et al. · 2019 · Cancer Immunology Research
  22. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells
    Sangya Agarwal, Maria Angela Aznar, Andrew J. Rech, Charly Ryan Good, Shunichiro Kuramitsu, Tong Da, Mercy Gohil, Linhui Chen, Seok-Jae Albert Hong, Pranali Ravikumar et al. · 2023 · Immunity
  23. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity
    Anthony Richard Cillo, Carly Cardello, Feng Shan, Lilit Karapetyan, Sheryl R. Kunning, Cindy Sander, Elizabeth A. Rush, Arivarasan D. Karunamurthy, Ryan Campbell Massa, Anjali Rohatgi et al. · 2024 · Cell
  24. Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells
    Dovedi, Simon J., Elder, Matthew J., Yang, Chunning, Sitnikova, Suzanne I., Irving, Lorraine, Hansen, Anna, Hair, James, Jones, Des C., Hasani, Sumati, Wang, Bo et al. · 2021 · Cancer Discovery
  25. SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
    Zhao, Mingxia, Guo, Wenjie, Wu, Yuanyuan, Yang, Chenxi, Zhong, Liang, Deng, Guoliang, Zhu, Yuyu, Liu, Wen, Gu, Yanhong, Lu, Yin et al. · 2019 · Acta Pharmaceutica Sinica B
  26. Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1
    Chamoto, Kenji, Yaguchi, Tomonori, Tajima, Masaki, Honjo, Tasuku · 2023 · Nature Reviews Immunology
  27. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
    Annika De Sousa Linhares, Claire Battin, Sabrina Jutz, Judith Maria Leitner, Christine Häfner, Joshua Tobias, Ursula Wiedermann, Michael Kundi, Gerhard J. Zlabinger, Katharina Grabmeier‐Pfistershammer et al. · 2019 · Scientific Reports
  28. Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
    Keisuke Onoi, Yusuke Chihara, Junji Uchino, Takayuki Shimamoto, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Tadaaki Yamada, Koichi Takayama · 2020 · Journal of Clinical Medicine
  29. PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity
    Doumet Georges Helou, Pedram Shafiei-Jahani, Richard Lo, Emily Diane Howard, Benjamin P. Hurrell, Lauriane Galle-Treger, Jacob Dean Painter, Gavin M. Lewis, Pejman Soroosh, Arlene H. Sharpe et al. · 2020 · Nature Communications
  30. Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas
    Yibo Yin, Alina C. Boesteanu, Zev A. Binder, Chong Bing Xu, Reiss A. Reid, Jesse L. Rodriguez, Danielle R. Cook, Radhika Thokala, Kristin Blouch, Bevin McGettigan-Croce et al. · 2018 · Molecular Therapy — Oncolytics
  31. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer
    Ge Qin, Xin Wang, Shubiao Ye, Yizhuo Li, Miao Chen, Shusen Wang, Tao Qin, Changlin Zhang, Yixin Li, Long Qian et al. · 2020 · Nature Communications
  32. Targeting SHP2 as a promising strategy for cancer immunotherapy
    Qianqian Liu, Jiao Qu, Mingxia Zhao, Qiang Xu, Yang Sun · 2019 · Pharmacological Research
  33. Interaction of SHP‐2 SH2 domains with PD‐1 ITSM induces PD‐1 dimerization and SHP‐2 activation
    Patsoukis, Nikolaos, Duke-Cohan, Jonathan S., Chaudhri, Apoorvi, Aksoylar, Halil-Ibrahim, Wang, Qi, Council, Asia, Berg, Anders, Freeman, Gordon J., Boussiotis, Vassiliki A. · 2020 · Communications Biology
  34. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives
    Lidia Yshii, Reinhard Hohlfeld, Roland Liblau · 2017 · Nature Reviews Neurology
  35. Inhibitors of the PD-1 Pathway in Tumor Therapy
    Martin W. LaFleur, Yuki Muroyama, Charles G. Drake, Arlene H. Sharpe · 2018 · The Journal of Immunology
  36. Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
    Amy L. Shergold, Rhona Millar, Robert J. B. Nibbs · 2019 · Pharmacological Research
  37. Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy
    Jii Bum Lee, Hye Ryun Kim, Sang‐Jun Ha · 2022 · Immune Network
  38. PD-1 Primarily Targets TCR Signal in the Inhibition of Functional T Cell Activation
    Reina Mizuno, Daisuke Sugiura, Kenji Shimizu, Takumi Maruhashi, Mizuki Watada, Il‐mi Okazaki, Taku Okazaki · 2019 · Frontiers in Immunology
  39. Senescent T cells: a potential biomarker and target for cancer therapy
    Jie Zhang, Tianhui He, Lixiang Xue, Hongyan Guo · 2021 · EBioMedicine
  40. Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials
    Zhenyi Niu, Runsen Jin, Yan Zhang, Hecheng Li · 2022 · Signal Transduction and Targeted Therapy
  41. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling
    Liu, Chen, Lu, Hengyu, Wang, Hongyun, Loo, Alice, Zhang, Xiamei, Yang, Guizhi, Kowal, Colleen, Delach, Scott, Wang, Ye, Goldoni, Silvia et al. · 2021 · Clinical Cancer Research
  42. Chronic Adrenergic Stress Contributes to Metabolic Dysfunction and an Exhausted Phenotype in T Cells in the Tumor Microenvironment
    Guanxi Qiao, Minhui Chen, Hemn Mohammadpour, Cameron R. MacDonald, Mark J. Bucsek, Bonnie Lee Hylander, Joseph J. Barbi, Elizabeth A. Repasky · 2021 · Cancer Immunology Research
  43. The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy
    Arabella Young, Zoe Quandt, Jeffrey A. Bluestone · 2018 · Cancer Immunology Research
  44. Counteracting CAR T cell dysfunction
    Mansour Poorebrahim, Jeroen Melief, Yago Pico de Coaña, Stina Linnea Wickström, Angel Cid Arregui, Rolf W. Kiessling · 2020 · Oncogene
  45. Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8 <sup>+</sup> T cell dysfunction and maintain memory phenotype
    Wang, Bei, Zhang, Wen, Jankovic, Vladimir, Golubov, Jacquelynn, Poon, Patrick, Oswald, Erin M., Gurer, Cagan, Wei, Joyce, Ramos, Ilyssa, Wu, Qi et al. · 2018 · Science Immunology
  46. Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity
    Brendan L. Horton, Jason B. Williams, Alexandra Cabanov, Stefani Spranger, Thomas Frank Gajewski · 2017 · Cancer Immunology Research
  47. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
    Kimio Yonesaka, Koji Haratani, Shiki Takamura, Hitomi Sakai, Ryoji Kato, Naoki Takegawa, Takayuki Takahama, Kaoru Tanaka, Hidetoshi Hayashi, Masayuki Takeda et al. · 2018 · Clinical Cancer Research
  48. Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity
    Linlin Sun, Chia-Wei Li, Ezra M. Chung, Ri‐Yao Yang, Yong‐Soo Kim, Andrew H Park, Yun‐Ju Lai, Yi Yang, Yu-Han Wang, Jielin Liu et al. · 2020 · Cancer Research
  49. The Role of Exosomes and Their Applications in Cancer
    Yuju Zhou, Ying Zhang, Huan Gong, Siqi Luo, Yan Ting Cui · 2021 · International Journal of Molecular Sciences
  50. Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
    Roberto Ferrara, Marie Naigeon, Édouard Auclin, Boris Duchemann, Lydie Cassard, Jean-Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Aude Desnoyer, Laura Mezquita et al. · 2020 · Clinical Cancer Research
  51. Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo
    Rota, Giorgia, Niogret, Charlène, Dang, Anh Thu, Barros, Cristina Ramon, Fonta, Nicolas Pierre, Alfei, Francesca, Morgado, Leonor, Zehn, Dietmar, Birchmeier, Walter, Vivier, Eric et al. · 2018 · Cell Reports
  52. Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches
    Paola Fisicaro, Valeria Barili, Marzia Rossi, Ilaria Montali, Andrea Lorenzo Vecchi, Greta Acerbi, Diletta Laccabue, Alessandra Zecca, Amalia Penna, Gabriele Missale et al. · 2020 · Frontiers in Immunology
  53. Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy
    Jiaqi Li, Jie Qing Eu, Li Ren Kong, Lingzhi Wang, Yaw Chyn Lim, Boon Cher Goh, Andrea Li‐Ann Wong · 2020 · Molecules
  54. Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein
    Wang, Mingliang, Lu, Jianfeng, Wang, Mi, Yang, Chao-Yie, Wang, Shaomeng · 2020 · Journal of Medicinal Chemistry
  55. Mechanisms of T-Cell Exhaustion in Pancreatic Cancer
    Didem Saka, Muazzez Gökalp, Betül Piyade, Nedim Can Çevik, Elif Arik Sever, Derya Unutmaz, Guralp Onur Ceyhan, İhsan Ekin Demir, Hande Asimgil · 2020 · Cancers
  56. The Role of Antigen Spreading in the Efficacy of Immunotherapies
    Peter Brossart · 2020 · Clinical Cancer Research
  57. Assessment of the expression of the immune checkpoint molecules PD‐1, CTLA4, TIM‐3 and LAG‐3 across different cancers in relation to treatment response, tumor‐infiltrating immune cells and survival
    Tu, Lei, Guan, Renguo, Yang, Hanting, Zhou, Yu, Hong, Weifeng, Ma, Liheng, Zhao, Guangzhe, Yu, Min · 2020 · International Journal of Cancer
  58. Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells
    Ling Wu, Qianru Wei, Joanna Brzostek, Nicholas R. J. Gascoigne · 2020 · Cellular and Molecular Immunology
  59. Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy
    Celis-Gutierrez, Javier, Blattmann, Peter, Zhai, Yunhao, Jarmuzynski, Nicolas, Ruminski, Kilian, Grégoire, Claude, Ounoughene, Youcef, Fiore, Frédéric, Aebersold, Ruedi, Roncagalli, Romain et al. · 2019 · Cell Reports
  60. CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy
    Monika Christine Brunner-Weinzierl, Christopher E. Rudd · 2018 · Frontiers in Immunology
  61. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis
    Xiaoying Sun, Raheleh Roudi, Ting Dai, Shangya Chen, Bin Fan, Hongjin Li, Yaqiong Zhou, Min Zhou, Bo Zhu, Chengqian Yin et al. · 2019 · BMC Cancer
  62. Beyond TCR Signaling: Emerging Functions of Lck in Cancer and Immunotherapy
    Ursula Bommhardt, Burkhart L. Schraven, Luca Simeoni · 2019 · International Journal of Molecular Sciences
  63. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity
    Alexander H. Morrison, Mark S. Diamond, Ceire A. Hay, Katelyn T. Byrne, Robert H. Vonderheide · 2020 · Proceedings of the National Academy of Sciences
  64. PD-1 blockade exacerbates Mycobacterium tuberculosis infection in rhesus macaques
    Keith D. Kauffman, Shunsuke Sakai, Nickiana E. Lora, Sivaranjani Namasivayam, Paul J. Baker, Olena Kamenyeva, Taylor W. Foreman, Christine E Nelson, Deivide Oliveira-de-Souza, Caian L. Vinhaes et al. · 2021 · Science Immunology
  65. Not All Immune Checkpoints Are Created Equal
    Annika De Sousa Linhares, Judith Maria Leitner, Katharina Grabmeier‐Pfistershammer, Peter Steinberger · 2018 · Frontiers in Immunology
  66. Regulatory T Cells in Cancer
    Plitas, George, Rudensky, Alexander Y. · 2020 · Annual Review of Cancer Biology
  67. JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions
    Takayuki Yoshino, G. Pentheroudakis, Saori Mishima, Michael James Overman, Kun‐Huei Yeh, Eishi Baba, Yoichi Naito, Fabien M. Calvo, Ajit Kumar Saxena, L.-T. Chen et al. · 2020 · Annals of Oncology
  68. Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy
    Marianne Weulersse, Assia Asrir, Andrea Pichler, Lea Lemaitre, Matthias Braun, Nadège Carrié, Marie-Véronique Joubert, Marie Le Moine, Laura Do Souto, Guillaume Gaud et al. · 2020 · Immunity
  69. Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer
    Grégoire de Streel, Charlotte Bertrand, Nicolas Chalon, Stéphanie Liénart, Orian Bricard, Sara Lecomte, Julien Devreux, Mélanie Gaignage, Gitte De Boeck, Lore Mariën et al. · 2020 · Nature Communications
  70. The opposing roles of CD 4+ T cells in anti‐tumour immunity
    Tomasz Ahrends, Jannie G. Borst · 2018 · Immunology
  71. NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer
    Bérengère Salomé, John P. Sfakianos, Daniel L Ranti, Jorge Daza, Christine Bieber, Andrew Charap, Christian Hammer, Romain Banchereau, Adam M. Farkas, Dan Fu Ruan et al. · 2022 · Cancer Cell
  72. T cell dysfunction and therapeutic intervention in cancer
    Caitlin C. Zebley, Dietmar Zehn, Stephen M Gottschalk, Hongbo Chi · 2024 · Nature Immunology
  73. Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies
    Zhendong Song, Meijing Wang, Ge Yang, Xue-Ping Chen, Ziyang Xu, Yang Sun, Xiao‐Feng Xiong · 2020 · Acta Pharmaceutica Sinica B
  74. Targeting immune checkpoints in hematological malignancies
    Basit Salik, Mark John Smyth, Kyohei Nakamura · 2020 · Journal of Hematology & Oncology
  75. Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders
    Stephanie M. Stanford, Nunzio Bottini · 2023 · Nature Reviews Drug Discovery
  76. The B7:CD28 family and friends: Unraveling coinhibitory interactions
    Kelly P. Burke, Apoorvi Chaudhri, Gordon James Freeman, Arlene H. Sharpe · 2024 · Immunity
  77. PD-1 hi CD8 + resident memory T cells balance immunity and fibrotic sequelae
    Zheng Wang, Shaohua Wang, Nick P. Goplen, Chaofan Li, In Su Cheon, Qigang Dai, Su Huang, Jinjun Shan, Chaoyu Ma, Zhenqing Ye et al. · 2019 · Science Immunology
  78. Reinvigorating exhausted CD8 + cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy
    Md Amir Hossain, Guilai Liu, Beiying Dai, Yaxuan Si, Qitao Yang, Junaid Wazir, Lutz Birnbaumer, Yong Yang · 2020 · Medicinal Research Reviews
  79. Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells
    William R. Strohl, Michael F. Naso · 2019 · Antibodies
  80. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
    Wenjing Qian, Mingfang Zhao, Ruoyu Wang, Heming Li · 2021 · Journal of Hematology & Oncology
  81. Dual Allosteric Inhibition of SHP2 Phosphatase
    Michelle Fodor, Edmund V. Price, Ping Wang, Hengyu Lu, Andreea Argintaru, Zhouliang Chen, Meir Glick, Huai-Xiang Hao, Mitsunori Kato, Robert Koenig et al. · 2018 · ACS Chemical Biology
  82. PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2
    Xiaozheng Xu, Bowen Hou, Amitkumar Fulzele, Takeya Masubuchi, Yunlong Zhao, Zijun Wu, Yanyan Hu, Yong Jiang, Yanzhe Ma, Haopeng Wang et al. · 2020 · The Journal of Cell Biology
  83. PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells
    Chaido Stathopoulou, Arunakumar Gangaplara, Grace Mallett, Francis A. Flomerfelt, Lukasz P. Liniany, David Knight, Leigh Samsel, Rolando Berlinguer Palmini, Joshua J. Yim, Tania C. Felizardo et al. · 2018 · Immunity
  84. PD‑L1 expression levels on tumor cells affect their immunosuppressive activity
    Zheng Yang, You‐Chen Fang, Jing Li · 2019 · Oncology Letters
  85. A dynamic CD2-rich compartment at the outer edge of the immunological synapse boosts and integrates signals
    Philippos Demetriou, Enas Abu‐Shah, Salvatore Valvo, Sarah McCuaig, Viveka Mayya, Audun Sverre Kvalvaag, Thomas Starkey, Kseniya Korobchevskaya, Lennard Y. W. Lee, Matthias Friedrich et al. · 2020 · Nature Immunology
  86. Recent Advances and Challenges in Cancer Immunotherapy
    Chelsea M. Peterson, Nathan Denlinger, Yiping Yang · 2022 · Cancers
  87. Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment
    John David Klement, Priscilla S. Redd, Chunwan Lu, Alyssa D. Merting, Dakota B. Poschel, Dafeng Yang, Natasha M. Savage, Gang Zhou, David H. Munn, Padraic G. Fallon et al. · 2023 · Cancer Cell
  88. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment
    Giulia Di Dalmazi, Silvia Ippolito, Isabella Lupi, Patrizio Caturegli · 2019 · Expert Review of Endocrinology & Metabolism
  89. CoViD-19 Immunopathology & Immunotherapy
    Francesco Chiappelli · 2020 · Bioinformation
  90. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
    Aitziber Buqué, Norma Bloy, Fernando Aranda, Francesca Castoldi, Alexander M.M. Eggermont, Isabelle Cremer, Wolf H. Fridman, Jitka Palich Fucikova, Jérôme Galon, Aurélien Marabelle et al. · 2015 · OncoImmunology
  91. Pancreatic Cancer and Immunotherapy: A Clinical Overview
    Florentine E. F. Timmer, Bart Geboers, Sanne Nieuwenhuizen, Madelon Dijkstra, Evelien A. C. Schouten, Robbert S. Puijk, Jan J.J. de Vries, M. Petrousjka van den Tol, Anna M E Bruynzeel, Mirte Mayke Streppel et al. · 2021 · Cancers
  92. Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment
    Kerr, D. Lucas, Haderk, Franziska, Bivona, Trever G. · 2021 · Current Opinion in Chemical Biology
  93. Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
    Yu, Chune, Liu, Xiaowei, Yang, Jiqiao, Zhang, Min, Jin, Hongyu, Ma, Xuelei, Shi, Hubing · 2019 · Frontiers in Immunology
  94. DNA probes that store mechanical information reveal transient piconewton forces applied by T cells
    Rong Ma, Anna V. Kellner, Victor Pui-Yan Ma, Hanquan Su, Brendan R. Deal, Joshua M. Brockman, Khalid S. Salaita · 2019 · Proceedings of the National Academy of Sciences
  95. The PD-1 Pathway Regulates Development and Function of Memory CD8+ T Cells following Respiratory Viral Infection
    Kristen E. Pauken, Jernej Godec, Pamela M. Odorizzi, Keturah E. Brown, Kathleen B. Yates, Shin Foong Ngiow, Kelly P. Burke, Seth Maleri, Shannon M. Grande, Loise M. Francisco et al. · 2020 · Cell Reports
  96. Mechanisms of resistance to immune checkpoint inhibitors
    Joji Nagasaki, Takamasa Ishino, Yosuke Togashi · 2022 · Cancer Science
  97. Immune receptor inhibition through enforced phosphatase recruitment
    Ricardo A. Fernandes, Leon Su, Yoko Nishiga, Junming Ren, M. Aladdin Bhuiyan, Ning Cheng, Calvin Jay Kuo, Lora K. Picton, Shozo Ohtsuki, Robbie G. Majzner et al. · 2020 · Nature
  98. Siglec receptors as new immune checkpoints in cancer
    Michal A. Stanczak, Heinz Philipp Laubli · 2022 · Molecular Aspects of Medicine
  99. Selective inhibition of low-affinity memory CD8(+) T cells by corticosteroids
    Tokunaga, Akihiro, Sugiyama, Daisuke, Maeda, Yuka, Warner, Allison Betof, Panageas, Katherine S., Ito, Sachiko, Togashi, Yosuke, Sakai, Chika, Wolchok, Jedd D., Nishikawa, Hiroyoshi · 2019 · Journal of Experimental Medicine
  100. Cancer Metabolism Drives a Stromal Regenerative Response
    Simon Schwörer, Santosha Adipudi Vardhana, Craig B. Thompson · 2019 · Cell Metabolism